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The ABO blood group system revisited:  a 
review and update
J.R. Storry and M.L. Olsson
The antigens of the ABO system were the first to be recognized as 
blood groups and actually the first human genetic markers known. 
Their presence and the realization of naturally occurring antibod-
ies to those antigens lacking from the cells made sense of the 
erratic failure of blood transfusion hitherto and opened up the 
possibility of a safe treatment practice in life-threatening blood 
loss. Although initially apparently simple, the ABO system has 
come to grow in complexity over the years. The mass of knowl-
edge relating to carbohydrate chemistry, enzymology, molecular 
genetics, and structural and evolutionary biology is now enormous 
thanks to more than a century of research using ABO as a principal 
model. This has provided us with data to form a solid platform 
of evidence-based transfusion and transplantation medicine used 
every day in laboratories and clinics around the globe. This review 
aims to summarize key findings and recent progress made toward 
further understanding of this surprisingly polymorphic system. 
Immunohematology 2009;25:48–59.
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There have been many reviews of the ABO blood group system written throughout the years, covering dif-ferent aspects of this fascinating topic. A limited se-
lection of such reviews can be found in the reference list, 
particularly for readers who want to focus more on the dis-
covery,1 biochemistry,2,3 enzyme structure,4 and molecular 
genetics.5,6 Our intention is not to reproduce them but to 
follow the guidelines of this new series of blood group sys-
tematic reviews in Immunohematology to provide a brief 
introduction to this amazingly complex blood group system.
History
 The discovery of the ABO blood group system ranges 
from myth and folk legend all the way to the Nobel Prize. Karl 
Landsteiner, a Viennese pathologist, made the observation 
that when his serum and that of five colleagues were mixed 
individually with their saline-suspended RBCs, agglutina-
tion was observed with some mixtures but not with others. 
He reported this as a footnote to a paper published in 19007 
followed by a more comprehensive paper in 1901.8 Transla-
tions of both papers can be found in the review by Camp 
and Ellis.1 In these early studies, he showed that two each 
of the six sera discriminated among three blood groups: A, 
B, and C (later renamed O from the German ohne, meaning 
without). Thus, Landsteiner demonstrated that a person’s 
serum contained antibodies to the antigen(s) lacking from 
their RBCs. The fourth blood group, AB, was described a 
year later by Decastello and Sturli9 in four individuals in a 
larger study of 34 healthy subjects and 121 patients.
 Variation in A antigen expression was also recognized 
very early in the twentieth century (reviewed in Race and 





.1,11 Other descriptions of weakened A antigen expression 
followed, and the A blood group was subdivided further 
based on characteristic reactivity with human polyclonal 
antisera, i.e., strength of reactivity and presence of mixed 
field agglutination; presence of anti-A
1
; and whether A or H 
blood group substance was present in the saliva of secretor 
subjects (Table 1). Weak forms of B antigen were also found 
but are typically more difficult to define serologically into 
specific categories although some subgroups (e.g., B
el
) are 
analogous to their A counterparts (A
el
).









B, and O) varies greatly among different popula-
tions.12,13 Populations with a high frequency of A phenotype 
are found mainly in Northern and Central Europe, and the 
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Anti-A Anti-A,B Anti-A1 Anti-H
A1 ++++ ++++ ++++ 0 A, H No
A2 ++++ ++++ 0 ++++ A, H Some-
times
Aint ++++ ++++ ++(+) +++ A, H No
A3 ++(+) 
mf ++(+)mf 0 ++++ A, H Some-
times
Ax 0/+ ++(+) 0 ++++ H Often
Aend + + 0 ++++ H Some-
times
Am 0/+ 0/+ 0 ++++ A, H No
Afinn + + 0 ++++ H Yes
Abantu +(+) +(+) 0 ++++ H Yes
A1ae 0
‡ 0 +++** ++++ H Yes***
Ay 0
‡ 0 0 ++++ A, H No
Ael 0
‡ 0 0 ++++ H Some-
times
*A negative reaction is denoted by 0. Positive reactions are denoted 
as from + (weak agglutination) to ++++ (maximal agglutination).
**Dolichos biflorus only.
***Serum reactivity against both A1 and A2 RBC.
†Blood group ABO substances in saliva and other body fluids of 
secretors.
‡Despite lack of agglutination, anti-A can be adsorbed to and eluted 
from cells in this subgroup.
mf = mixed field agglutination.
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A
2
 phenotype reaches its peak among the Lapps in North-
ern Scandinavia but is very rare in Asia. The B phenotype 
is most frequent in Central Asia and almost absent in Am-
erindians. Blood group O is the most frequent phenotype 
in a global perspective, with Native American Indians be-
ing almost exclusively blood group O. Parts of Africa and 
Australia also show high frequencies of blood group O. The 
reason for the differences observed among populations is 
not fully understood although several theories have arisen. 
The concept of evolutionary selection based on pathogen-
driven blood group changes will be discussed later (see 
section on pathogen interactions). The early importance of 
ABO diversity is supported by reports in which the group 
O-defining single base pair deletion at nucleotide position 
261 (see section on molecular genetics) has been found in 
both Neandertal people14 and ancient Egyptian mummies,15 
suggesting that selection pressure and survival of the fittest 
were indeed early features during our co-evolution with 
pathogens like malaria parasites and many others.
Nomenclature
 The ABO system was the first to be discovered and has 
therefore been given the number 001 in the official Inter-
national Society of Blood Transfusion (ISBT) terminology. 
Nomenclature for the ABO antigens is actually straightfor-
ward since the antigen status is determined by the pres-
ence or absence of specific carbohydrate molecules. This is 
particularly true for the A and B antigens but may be less 
clear for the two other antigens (A,B and A1) given official 
antigen status by the ISBT. The A,B antigen is thought to 
be an epitope not involving the A versus B–differentiating 
surfaces, but consists of a common recognition motif16 
found when either the A or B antigens are present. The de-
bate surrounding the real identity of the A1 antigen is still 
ongoing,17,18 but the A
1
 phenotype reveals many differences 
compared with A
2
, both quantitative and qualitative, so the 
question is quite complex (see section on biochemistry). 
Table 2 shows both the numerical and traditional nomen-
clature according to the ISBT Working Party on Terminol-
ogy for Red Cell Surface Antigens.19
 Blood group allele nomenclature including ABO is un-
der consideration by a subcommittee of the aforementioned 
ISBT Working Party. In the absence of an officially agreed-
on terminology, several different variants have evolved (see 
Table 7 in Chester and Olsson6). Typically, alleles are re-
ferred to by their serologic activity and a number. An un-
official but often used terminology is found at the Blood 
Group Antigen Gene Mutation Database, also known as the 
dbRBC Web site (http://www.ncbi.nlm.nih.gov/projects/
gv/rbc20). In this review, alleles will be referred to in the 
traditional way but with dbRBC terminology given in brack-
ets, e.g., A1 [A101] and O1 [O01].
 It can be specifically noted that it is important for clar-
ity and consistency to use subscripts, superscripts, and 
italics appropriately. For example, A1, A
1
, and A1 mean the 
antigen, the phenotype, and the allele, respectively.
Inheritance and Molecular Genetics
 The A and B antigens are inherited as Mendelian char-
acteristics in a codominant autosomal fashion. In 1908, Ep-
stein and Ottenberg21 were the first to suggest in a short case 
report that ABO blood groups might be inherited. This was 
later proved by von Dungern and Hirszfeld in 1910 (trans-
lated by Pohlmann22). In fact, ABO inheritance was one of 
the first genetic markers to be used in paternity testing and 
in forensic medicine.23,24
 Unlike the majority of blood groups, the antigens of the 
six currently known carbohydrate systems are not coded 
by genes directly. Instead, these blood group genes encode 
glycosyltransferases that in turn synthesize the oligosac-
charide epitopes (Fig. 1). Thus, the A and B antigens are 
made by A and B glycosyltransferase, respectively, encoded 
by the ABO gene carried on the long arm of chromosome 9 
(9q34). As with many of the blood group genes, the position 
of the ABO locus was known for many years before the gene 
was cloned.25 The genes encoding the A-synthesizing 3-α-N-
acetylgalactosaminyltransferase and the B-synthesizing 
3-α-N-galactosaminyltransferase were cloned by Yamamo-
to and colleagues in 199026,27 after purification and partial 
amino acid sequencing of A transferase from lung tissue.28 
Probing cDNA libraries obtained from human adenocar-
cinoma cell lines of different ABO types, the main alleles 
were defined.26 They determined that the B-specific mRNA 
differed from the A-specific gene by only 7 of 1062 coding 
nucleotides, of which 4 result in amino acid differences in 
the enzyme product. The difference between the A1 [A101] 
and O1 [O01] genes was shown to be a single guanosine (G) 
deletion, which alters and severely truncates the open reading 
frame (ORF) as shown in Figure 2. The A
2
 phenotype was 
shown to depend on a cytosine deletion in the 5′ end of the 
gene, resulting in elongation of the ORF.29 The organization 
of the ABO locus30,31 is shown in Figure 3. The gene consists 
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Fig. 1 Principal 
structure of the A, B, 
and H oligosaccha-
rides. The difference 
between the A and 
B structures is high-
lighted by arrows.
Table 2. ABO nomenclature
System ABO antigen notation
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of seven exons (plus an alternative exon 1a located upstream 
of exon 132), with the majority of the catalytic domain of the 
enzyme encoded by exon 7.
 Since the groundbreaking cloning paper, 215 ABO se-
quence entries have been submitted to the dbRBC Web 
site20 (accessed on April 15, 2009) and curated by the dbR-
BC staff and experts, but new alleles are constantly being 
identified. Figure 4 shows a breakdown of the 181 alleles 
in the dbRBC categorized by their association with normal 
or altered phenotypes: these include 65 different A alleles, 
47 B alleles, 58 O alleles, and 11 “AB” alleles. The remain-
ing 34 sequences listed in the current dbRBC consist of 20 
sequences encompassing the 5′ noncoding region including 
the repetitive and polymorphic CCAAT box binding fac-
tor/nuclear factor Y (CBF/NF-Y) motif and 14 intronic or 





 phenotypes on RBCs, respectively, whereas 48 
describe mutated A alleles (Aweak) associated with different 
variants of weak A antigen expression (Table 1); the B al-
leles include 9 normal and 38 weak alleles; and 11 alleles 
have been described that encode glycosyltransferases ca-
pable of synthesizing easily detectable levels of both A and 
B antigens. This group includes alleles conveying the two 
unusual phenotypes cisAB and B(A). Fifty-eight alleles are 
predicted to give rise to proteins without enzymatic activity 
of which 45 contain 261delG, the mutation that alters the 
translational ORF and predicts a shortened protein product 
with no transferase activity. This large group of O alleles 
includes four principally important evolutionary lineages: 
O1 [O01], O1v [O02], Otlse09 or O1(467T;318T) [O09], and O1bantu 
[O54].33,34 Numerous minor variants of these main alleles35 
as well as hybrid O alleles combining A2 or B with different 
261delG-containing O sequences36 have also been found, 
most notably in individuals of African ancestry. Of the re-
maining 13 “nondeletional” alleles, 3 suffer similar fates to 
that caused by 261delG because they contain nonsense mu-
tations resulting in altered ORFs caused by nucleotide in-
sertions. Another 3 have nonsense mutations introducing 
immediate stop codons, thereby truncating the ORF at the 
same codon where they occur. Finally, 7 recorded nonde-
letional O alleles are crippled by at least one missense mu-
tation each, giving rise to critical amino acid substitutions, 
the most famous example of which is 802G>A resulting in 
268Arg. For a recent review about this latter group of inter-
esting O alleles designated O2 [O03], see Yazer and Olsson.37 
What is most intriguing about these nondeletional O alleles 
is that they are all attributable to mutations in A allele back-
bone sequences. This has two main practical consequences: 
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Fig. 4 Graphic representation showing the number of ABO alleles 
currently listed in the dbRBC database. The black bars represent al-
leles that encode a glycosyltransferase with normal activity; the white 
bars represent alleles encoding glycosyltransferases that have altered 
activity or specificity. The AB bar includes alleles encoding glycosyl-
transferases capable of synthesizing both A and B antigens, i.e., cisAB 
and B(A). The group O bar has been divided into the 45 O alleles 
that contain the mutation 261delG (black) and the 13 “nondeletional” 
alleles without it (white). The latter group is often associated with weak 
expression of A antigen.
Fig. 2 Schematic representation of predicted open reading frames 
for some common ABO alleles. White rectangles represent trans-
lated A1 [A101] consensus; black rectangles represent translated 
non-A1 consensus (nonsense). Vertical bars indicate nucleotide 
(nt) positions (given above bars) of mutations leading to amino acid 
changes. * indicates B [B01] allele is mutated at nt 796 and 803; 
O2 [O03] allele at nt 802.
Fig. 3 Organization of the ABO gene. A: The seven exons and six 
introns are not drawn to scale. The numerals above boxes represent 
the first and last nucleotides (nt) of the coding region in each exon, 
and those below boxes show the corresponding amino acid (a.a.) 
numbers. The size of each intron is indicated with a thin oblique bar. 
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presence of A1 or A2 alleles unless specifically designed 
to detect rare O alleles, which will result in the potentially 
catastrophic prediction of group A in a group O person. 
Second, the phenotype actually conveyed by inheritance of 
one of these so-called O alleles is not always O but often 
weak A or O-like but without anti-A present in plasma. The 
reason for this is currently unclear, but there has recently 
been a series of papers investigating the serologic pattern 
and mechanisms behind this interesting phenomenon.38–42 
There is currently no O allele described that is based on a B 
sequence, but we predict that when such an allele is found, 
it will show the opposite serology, i.e., either weak B expres-
sion or O-like without anti-B in plasma.
 It is the molecular genetics that make this system so fas-
cinating because mutations ranging from single nucleotide 
changes to more complex hybrid gene formations can alter 
the specificity of the enzyme, the efficacy of the enzyme, or 
both; changes that, at the phenotypic level, are manifested 
simply by altered antigen expression. Good examples are 
the various molecular bases of the A
x
 phenotype, which can 
either result from a single missense mutation in exon 7 of 
an A1 [A101] allele or be based on different hybrids, for in-
stance between the 5′ end of B and the 3′ end of O alleles.43,44 
The B
3
 phenotype in the Taiwanese population has also 
been shown to result from different molecular backgrounds, 
one a missense mutation but more commonly, a principally 
interesting mutation that was the first one shown to affect 
splicing of ABO mRNA and cause exon skipping.45 In ad-
dition to altered specificity or enzymatic efficacy, aberrant 
intracellular trafficking of ABO transferase may cause weak 
subgroup phenotypes.46
 As alluded to previously, this added layer of complexity, 
in which mutations affect enzyme activity and not the anti-
gen directly, provides difficulties in designing genotyping 
assays that will detect rare variants, which if misinterpreted 
can have serious consequences in ABO group determina-
tion.47
 There are problems associated with all the more than 
30 ABO genotype screening methods published or commer-
cially available so far (reviewed in Olsson and Chester48). 
The vast majority is only designed to determine between 
three and six of the common alleles, although additional 
alleles can often surface if their polymorphisms interfere 
with the detection system. However, virtually all methods 
will fail to predict the phenotype of a sample in the pres-
ence of most A/B subgroup alleles, rare nondeletional null 
alleles, cisAB and B(A) alleles, or hybrid alleles, which can 
lead to serious consequences. Because this is particularly 
dangerous if blood or transplant recipients are typed (as 
suggested, e.g., by Procter et al.49) we recently developed 
and implemented an improved ABO genotype screening 
method that addresses these problems and can be used in a 
clinical laboratory setting.47 In summary, the complex genet-
ics of ABO is a major challenge for ABO genotyping efforts, 
not least because of the disturbing fact that a certain allele 
can lead to more than one phenotype and seemingly identi-
cal phenotypes can have more than one molecular genetic 
background.
 The regulatory mechanism of the ABO gene has been 
investigated extensively. An enhancer element located ap-
proximately 4 kbp upstream of exon 150 was found to con-
tain four 43-bp repeats in all alleles except A1 [A101] and the 
infrequent O2 [O03], which have only one copy.51 This may 
play a role in expression.52 The enhancer region contains 
a CBF/NF-Y binding site; mutations in this site decrease 
enhancer activity in a gastric cancer cell line,50 and altera-
tions in this region may even cause rare B subgroup pheno-
types.53 However, it was recently shown that A1 [A101] or A2 
[A201] transcripts are virtually undetectable in peripheral 
blood whereas B and O (including O2 [O03]) mRNA is read-
ily found.54,55 This appears to speak against a critical role for 
CBF repeats in erythroid ABO regulation, but more work is 
required. There is also an Sp1-binding site in the proximal 
promoter that may be important for erythroid ABO regula-
tion.56
 Although much is understood regarding the cause of 
weak A/B antigen expression on RBCs when it comes to in-
herited weak ABO subgroups,5,6 less is known about altered 
ABO expression in hematologic disorders. Erythrocytes los-
ing A, B, or H antigen have been noted in patients with he-
matologic malignancy, especially in the myeloid lineage.57,58 
Very recently it was suggested that methylation of the ABO 
proximal promoter is the reason for such leukemia-associated 
downregulation.59 Reduced A and B antigen expression in 
bladder and oral carcinomas is partially attributable to loss 
of heterozygosity or hypermethylation.60,61 Furthermore, 
urothelial tumor tissue contains decreased amounts of A/B 
antigens that correlated to decreased levels of ABO mRNA 
compared with cells from normal tissue.62 Transient depres-
sion of A antigens has also been observed in some pregnant 
women,44 but the reason for this is still unknown.
Biochemistry
 The biochemistry of the A and B antigens was elucidat-
ed by the astonishingly early and brilliant work from the 
groups of Morgan and Watkins, and Kabat (reviewed by 
Watkins2 and Kabat63). The A, B, and H determinants were 
hypothesized to reside on water-soluble glycoproteins able 
to inhibit agglutination of RBCs by antibodies or lectins. 
A precursor substance, H, was hypothesized as a building 
structure for A and B, and the terms O- (or H-) substance 
and anti-H were introduced in 1948.64
 Owing to difficulties in obtaining sufficient quantities of 
blood group active material after extraction from RBCs, most 
of the early studies were performed on ovarian cyst or animal 
mucin, rich in secreted blood group substances. Before isola-
tion and chemical identification of these substances, inhibi-
tion with simple sugars indicated N-acetyl-d-galactosamine 
(GalNAc), d-galactose (Gal), and l-fucose (Fuc) as the defin-
ing sugars in blood groups A, B, and O, respectively.65,66
 Independent of the blood group of the individual 
investigated, a surprisingly similar composition of carbo-
ABO blood group system 
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hydrate residues (mainly Fuc, Gal, GalNAc and N-acetyl-
d-glucosamine [GlcNAc]) was found. This was taken as a 
sign of large similar precursor molecules carrying small 
residues that differentiate blood groups.67 The minimal 
determinant structures were subsequently shown to be 
trisaccharides as shown in Figure 1. The important concept 
of precursor-product relationship between H and A/B was 
formulated,67,68 and the critical role of nucleotide-bound 
sugars as substrates in oligosaccharide synthesis was appre-
ciated.69 The biosynthetic pathway of the ABO blood group 
structures is as outlined in Figure 5, and the presence of 
A and B glycosyltransferases was first predicted70 and then 
experimentally established.71–73 Thus, the A and B glycosyl-
transferases use UDP-GalNAc and UDP-Gal, respectively, 
as substrates. Both require the H determinant as acceptor. 
The O protein is nonfunctional, leaving the H-defining 
terminal Fuc unaltered.
 Although the composition of the A and B antigens is 
apparently straightforward, the biochemistry behind the 
shared A,B antigen recognized by many group O plasmas 
has only recently been elucidated experimentally. Bovin 
and his colleagues16 synthesized a deacetylated A trisaccha-
ride structure and bound it to the precursor in such a way 
as to expose what they hypothesized would be the common 
A,B epitope. They were able to demonstrate binding of both 
monoclonal and polyclonal anti-A,B to the synthetic struc-
ture.
 Although it is well known that there are approximately 
five times fewer A antigens on A
2
 than on A
1
 RBCs, the un-
derlying basis for the qualitative differences between them 
is less well defined. The A
2
 transferase is 10 times less ef-
ficient than the A
1
 transferase and has a different pH opti-
mum and pI.74,75 The A
2
 enzyme is also less able to use chains 
other than type 1 or 2 carbohydrate precursors like the ex-
tended type 3 (repetitive A) and type 4 (globo-A) chains on 
RBC glycolipids.17,76 More recently, Svensson et al.18 have 
produced somewhat contradictory data indicating that al-
though the A
2
 transferase can readily use H type 3 chains to 
synthesize A antigen, the low levels of type 4 chains remain 
unconverted.
 The ABH sugars are found on glycolipids (approximate-
ly 10%) and glycoproteins (approximately 90%) on the RBC 
as well as on many different tissues and cell types, including 
epithelial cells that line the lumen of the gastrointestinal, 
respiratory, and reproductive tracts as well as in salivary 
glands and skin. This wide distribution is a common fea-
ture for many of the carbohydrate blood groups, which has 
resulted in the term histo-blood group often being used to 
reflect this wide distribution. A and B antigen synthesis 
occurs during normal glycosylation of proteins and lipids 
in the Golgi compartment.77 The precursor H substance is 
synthesized by one of two fucosyltransferases depending on 
the acceptor substrate used. The FUT1 gene that encodes 
the 2-α-fucosyltransferase (α2FucT1) is responsible mainly 
for the synthesis of the H antigen on type 2 (and type 4) car-
bohydrate precursors found on RBCs.78 The closely related 
FUT2 gene encodes a very similar 2-α-fucosyltransferase 
(α2FucT2) that is expressed in epithelial cells and synthe-
sizes H antigen mainly on type 1 and type 3 chains.77 The 
major precursor types present in different tissues and 
secretions are shown in Table 3.
 In the Bombay phenotype (O
h
), a silenced FUT1 gene is 
present together with a silenced FUT2 gene. Because H an-
tigen is the precursor substrate for both A and B antigens, 
neither antigen can be synthesized without α2FucT activity, 
independent of the ABO genotype. The para-Bombay phe-
notype results from either (1) a silenced FUT1 gene present 
together with an active FUT2 gene, which permits the syn-
thesis of H type 1 (and therefore A/B antigens) that may be 
adsorbed onto the RBC from the plasma; or (2) a mutated 
FUT1 gene in which the encoded enzyme activity is greatly 
diminished, so that very low amounts of H antigen (and 
A/B antigen) are produced. It may be present with or with-
out an active FUT2 gene. In both cases, H antigen (and A/B 
antigen) is very weakly expressed and is often only detected 
by adsorption and elution tests with the appropriate blood 
group reagents. The H blood group system (ISBT 018) will 
be the subject of another review later in this Immunohematology 
series.
 The A and B glycosyltransferases are type II membrane 
proteins located in the Golgi compartment,79,80 although 
soluble forms are found in plasma and other body fluids. 
The enzyme consists of a short transmembrane domain, a 
stem region, and a catalytic domain that extends into the 
Golgi lumen (Fig. 6). The crystal structure elucidated by 
J.R. Storry and M.L. Olsson
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Fig. 5. Schematic depiction of the biosynthetic pathways for con-
version of H determinants to A or B determinants. R represents the 
core structure. See text for enzyme abbreviations.
Table 3. Peripheral core structures and their principal tissue 
distribution (modified from Clausen and Hakomori3)
Peripheral core type Structure Distribution
Type 1 Galβ1→3GlcNAcβ1→R Endodermal, secretions, 
plasma
Type 2 Galβ1→4GlcNAcβ1→R Ecto- and mesodermal 
(e.g., erythrocytes)
Type 3 Galβ1→3GalNAcα1→R O-linked mucin-type, 
repetitive A
Type 4 Galβ1→3GalNAcβ1→R Glycolipids in kidneys 
(and erythrocytes)
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Patenaude and colleagues81 showed that the catalytic site 
is divided into two domains; the N-terminal domain rec-
ognizes the nucleotide sugar donor substrate (UDP-Gal or 
UDP-GalNAc), whereas the acceptor substrate is held by 
the C-terminal domain. The DXD motif (DVD in these en-
zymes) that serves to capture Mn2+, essential to the reac-
tion because of its ability to bind the UDP part of the donor 
substrate, lies between the two domains. In addition, two 
so-called disordered loops have been identified by the crys-
tal structural studies. One is located at the C-terminal of the 
enzyme. The other disordered loop lies close to the catalytic 
site of the enzyme. Its role is unclear4; however, mutations 
in this region have been shown to reduce enzyme activity 
and are often associated with weak subgroup phenotypes.82
Antibodies in the System
 Anti-A and anti-B are naturally occurring antibodies 
that are produced by immunocompetent individuals from 
the age of approximately 6 months. The widely held dogma 
is that these antibodies are in fact mimicking antibodies 
produced against terminal carbohydrates on bacterial cell 
walls as a response to our normal intestinal microbial flora, 
and that these glycotopes share structural homology with A 
and B antigens.83 In a modern follow-up to this original con-
cept, three children with different congenital immune de-
fects were studied after apparent ABO grouping discrepan-
cies.84 These patients (age range, 1.7 to 8 years) were limited 
to total parenteral nutrition and tube feeding. Their RBCs 
typed as group A, but each child lacked the expected anti-B 
by routine testing, although anti-B was weakly detectable in 
the serum of one of them after prolonged incubation at 4°C. 
The authors concluded that the absence of dietary exposure 
to bacteria prevented the production of anti-B despite nor-
mal immunoglobulin levels in the patients’ sera. Recogni-
tion of self prevents an individual from making antibodies 
to antigens shared by the bacteria and may also partially 
explain disease susceptibility of one blood group over an-
other (discussed briefly in the next section).
 Anti-A and anti-B are predominantly IgM antibodies 
although IgG or IgA components are often found.85,86 Class-
switching to IgG does not occur unless there is a “hyperim-
munizing” event such as an ABO-incompatible pregnancy 
or transfusion. Absence of the expected antibodies occurs 
rarely, although antibody titers vary considerably among 
individuals and have been shown to diminish with age. Pa-
tients who have immunoglobulin deficiencies will also lack 
anti-A or anti-B. Otherwise, most often the absence of an 
agglutinin in a healthy person should be taken as an indi-
cation that there may be a weak antigen or even (micro) 
chimerism present, perhaps detectable by adsorption and 
elution or by flow cytometry.




B phenotypes as well as 
those whose RBCs carry certain A subgroups (Table 1) can 
also produce anti-A1, generally reactive at room tempera-
ture and below. Although ABO antibodies of IgG type can 
cross the placenta, severe ABO-related hemolytic disease 
of the newborn is not common. The mechanisms behind 
this are discussed in more detail in the section on clinical 
consequences.
Pathogen Interactions
 Bacteria, viruses, and parasites have been proposed as 
important driving forces for the geographic distribution of 
ABO blood group phenotypes because different pathogens 
demonstrate blood group–identical or –cross-reactive mol-
ecules on their surfaces. These are the probable targets for 
“blood group” antibodies, and their existence is the lead-
ing hypothesis as to why we make naturally occurring an-
tibodies against the carbohydrate blood groups we lack. In 
addition, many pathogens show selective binding to blood 
group carbohydrate moieties via lectins (reviewed by Gar-
ratty87). More recent but perhaps anecdotal evidence for 
this theory was provided after severe hemolytic transfusion 
reactions in two group B patients receiving apheresis plate-
lets from the same group A platelet donor.88 The donor had 
donated regularly for a period of 20 years, during which 
time no adverse effects of transfusion had been observed, 
but had recently begun to supplement his diet with high-
dose probiotics and his anti-B titer was shown to be greater 
than 8000. Inhibition studies performed with plasma from 
random group A donors and solubilized probiotic tablets 
demonstrated a reduction in titer, hinting at a role for ABO 
antibodies in neutralizing pathogens. This line of thinking 
is supported further by data from studies on viral glycosy-
lation in host cells. HIV cultured in vitro with peripheral 
blood mononuclear cells (PBMC) from donors of different 
ABO blood group system 
Fig. 6 A: The topology of the transferase is shown as a Golgi-local-
ized, membrane-bound enzyme with a cytoplasmic N-terminus and 
catalytic C-terminal domain (modified from Paulson and Colley79). 
B and C: The three-dimensional surface model (B) was created 
with the Deep View Swiss Pdb Viewer version 3.7, and the three-
dimensional ribbon structure (C) was generated using SETOR and 
SetoRibbon (unpublished). The vertical bar to the left illustrates 
the approximate exon usage for the different glycosyltransferase 
domains.
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ABO groups demonstrated specific neutralization with 
anti-A of those isolates grown in group A PBMCs but not 
those cultured with group B or group O cells.89 Measles vi-
rus, when cocultured in a system expressing ABH glycosyl-
transferases (to mimic an in vivo environment), expressed 
A or B epitopes, or not, according to the enzymes expressed. 
Viral particles could then be neutralized by normal poly-
clonal anti-A or anti-B sera in the presence of complement 
if the corresponding glycans were present.90 Conversely, 
the A and B (and H) antigens are also used as receptors for 
pathogen invasion by attachment to host cells as mentioned 
previously, so the equilibrium between invasion and eva-
sion is a fine balance on both sides.
 Furthermore, growing evidence for a leading role of 
Plasmodium falciparum as the major force shaping the hu-
man genome including the distribution of the blood groups 
has emerged.91,92 The parasite-induced RBC surface protein 
pfEMP1 is known to bind to the A antigen trisaccharide,93 
and it has been shown that the severity, including mortality, 
of malarial disease is significantly lower in group O children 
than in other groups, mainly through the mechanism of re-
duced rosetting.94,95 It is the focus on pediatric disease that 
is thought to make this pathogen particularly effective in 
exerting a selection pressure on our genome.
 The general theme here is the concept of herd immu-
nity, i.e., the fact that differences in the population will keep 
at least a fraction of all individuals protected from most if 
not all pathogens for humanity to survive. ABO differences 
as part of our innate immunity appear to be one of the bet-
ter examples of this idea.96
Clinical Significance
 Of all antibodies to RBC blood group antigens, anti-A 
and anti-B are arguably the most clinically important. On 
the other hand anti-A1 and anti-H are very seldom found 
to correlate with hemolytic adverse events but often show 
lower thermal optima. Before the discovery of ABO, trans-
fusion between humans had been attempted with mixed 
success. In some cases, the patient survived and got bet-
ter.  In others the patient died rapidly, which we now re-
alize was attributable to rapid intravascular hemolysis of 
ABO-incompatible RBCs (reviewed by Mollison et al.97). 
It has been reported that transfusion of as little as 30 mL 
of ABO-mismatched blood can result in a rapid fatal in-
travascular transfusion reaction (reviewed in Issitt and 
Anstee98). Together with transfusion-related acute lung 
injury (TRALI) and bacterial contamination of blood com-
ponents, ABO incompatibility is still one of the main risks 
for major morbidity and mortality associated with transfu-
sions, after erroneous transfusions.99,100 The latest FDA re-
port on transfusion-associated fatalities (found at http://
www.fda.gov/cber/blood/fatal08.htm) shows that blood 
group incompatibility was judged as the cause of death in 
37 percent of all cases during 2008, with TRALI at 35 per-
cent. Among the hemolytic fatalities ABO was the cause in 
59 percent. Surprisingly, however, many reports show that 
approximately 50 percent of patients who are inadvertently 
transfused with a major ABO-mismatched unit of blood tol-
erate the blood without any apparent signs of a transfusion 
reaction.101 The mechanisms underlying the ability of some 
individuals to tolerate ABO-mismatched blood are not well 
understood but are very interesting as identification of 
resistance markers could be exploited in transplantation 
therapy. Despite our relative sophistication in providing ap-
propriately ABO-matched blood for patients, there is recent 
clinical evidence that even the concept of ABO-compatible 
(as opposed to ABO-identical) products may not be as safe 
as it would appear. A study that followed the posttransfu-
sion mortality among more than 86,000 patients receiving 
plasma showed that exposure to ABO-compatible but non-
ABO-identical plasma was associated with an increased risk 
of death.102 Whether this is associated with immune com-
plexes between anti-A/B and soluble A/B antigen in AB 
plasma, for instance, remains to be studied. Furthermore, 
reports of the usage of platelet concentrates in cardiac 
surgery has also demonstrated less favorable outcomes in 
those patients receiving ABO-mismatched products.103 The 
authors hypothesized that the formation of immune com-
plexes may trigger cellular and inflammatory changes that 
adversely affect patient outcome.
 Hemolytic disease of the fetus and newborn (HDFN) as 
a result of ABO incompatibility between mother and baby 
is a relatively common event in group O mothers carrying a 
group A or group B fetus. However, the disease is generally 
mild and rarely requires treatment, most often by photo-
therapy,97 although inhibition of antibodies by administra-
tion of soluble A or B trisaccharides has been used success-
fully.104 Mild HDFN is a consequence of the comparatively 
low levels of IgG ABO antibodies (which are often mainly 
IgG2 or IgG4) capable of crossing the placenta and also is 
related to the immaturity of the glycosylated structures on 
fetal RBCs. In addition, ABH antigens are present on many 
other cell types so the antibody concentration on RBCs is 
limited and the DAT often only weakly positive.
 The clinical significance of anti-A and anti-B extends 
beyond transfusion medicine and is important in both solid 
organ and hematopoietic transplantation. Although ABO-
mismatched hematopoietic stem cell transplantation is 
standard practice with a favorable outcome in most cases, 
transplantation of ABO-incompatible solid organs has been 
established only relatively recently with moderately suc-
cessful outcome.105 Children younger than 3 years of age 
have been shown to tolerate mismatched organs better, and 
West and colleagues have demonstrated good posttrans-
plant survival in infants undergoing ABO-incompatible 
heart transplants,106 showing that the relatively immature 
B-cell response in these patients can be exploited.107 In a 
study of 46 patients undergoing ABO-mismatched renal 
transplants, Tobian et al.108 demonstrated that therapeu-
tic apheresis to reduce anti-A and anti-B titers to less than 
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16 together with standard immunosuppression protocols 
results in successful and stable engraftment. Progress 
continues in this field, driven by a shortage of appropriate 
organs for transplant. Yazer and Triulzi109 conclude that 
immune hemolysis remains a major complication in ABO-
mismatched transplantation of solid organs and to a lesser 
extent hematopoietic progenitor cells. However, passenger 
lymphocyte syndrome attributable to ABO or other blood 
group antibodies can now often be ameliorated by mono-
clonal antibody therapy, once clinicians realize the prob-
lem.
Summary and Future Perspectives
 Despite the relative simplicity of the A and B antigens, 
perhaps especially considering the minor biochemical dif-
ference between them, the ABO blood group system remains 
one of the most interesting, both clinically and scientifi-
cally, dividing the world’s population including patients 
and donors into four groups irrespective of origin or creed. 
Figure 7 summarizes the four principal levels at which the 
ABO system can be considered and shows how immunohe-
matologists have been able to exploit the steadily increasing 
knowledge of this system by devising tests taking advan-
tage of each of the different levels. It also shows some of the 
natural consequences generated and their relation to the 
microbes surrounding us.
 A whole array of ABO-related research and other proj-
ects is currently in progress. Even if a surprising number 
of ABO alleles has been discovered already, no doubt there 
are more to come. ISBT is currently working to facilitate 
communication and reporting by introducing an official al-
lele nomenclature. Although ABO genotyping cannot yet be 
used as a stand-alone analysis to support clinical decisions, 
improvement of the current status is highly desirable for 
its use as an independent addition to serology in the refer-
ence laboratory. Together with colleagues across Europe, 
we recently introduced the first microarray-based ABO typ-
ing system that takes the first steps toward this goal on a 
higher throughput system.110 Efforts to renew methods for 
serologic typing are also ongoing. For instance, the young 
field of microfluidics holds promise for alternative blood 
grouping technology being more rapid, using smaller vol-
umes of reactants, and being applicable to broader testing 
platforms.111
 The temptation to create ABO-universal blood for 
transfusion purposes has kept scientists busy since the 
early 1980s when the first successful report of deliberate 
transfusion with modified RBCs across the ABO barrier was 
published.112 Progress from those early days, using a poorly 
effective B-converting exoglycosidase from green coffee 
beans, has continued with the aims of eliminating ABO-
associated hemolytic transfusion reactions and simplify-
ing blood logistics and inventory management. Not only 
has the process taken important strides toward becoming 
a reality with both A- and B-degrading enzymes recombi-
nantly available and necessary clinical trials in progress or 
being designed, but the project has also brought with it the 
scientifically exciting discovery of a large new class of bac-
terially derived exoglycosidase enzymes unknown hitherto 
and without clear homology or resemblance to any other 
group of molecules.113,114 It is unknown at this point why so 
many different bacterial species have developed these blood 
group–converting enzymes. Speculation includes that it 
would simply be a means of digesting potential nutrient 
saccharides, but it also may be yet another way for microbes 
to make sure they are able to attach to the host cell surface, 
even if the histo-blood group of the current host happens 
not to fit the bacterial lectins initially. It is actually quite 
likely that yet other glycosidase specificities will be found 
in this extended arsenal of newly discovered enzymes. A 
recently exploited example is the Galα3Gal (also known as 
the straight B, fucose-less B, or Galili antigen) -degrading 
enzyme subfamily of galactosidases that can, for instance, 
be used to degrade xenograft antigenicity in pig tendons for 
use in knee surgery.115
 Finally, it is easy to make the mistake of sitting back 
and looking at the ABO system as close to complete when 
it comes to knowledge and discovery. We predict that both 
the antigenic diversity and the way we look at antibody 
specificities in this and related systems will change dramat-
ically during the next few years based on recent and future 
findings made possible by new technologies. ABO has for a 
long time served as a great model for genetics, enzymology, 
and biochemistry thanks to our deep understanding of the 
interindividual variation in this system, and there is noth-
ing to suggest that it will stop now when high-throughput 
genetics and glycotope arrays are here to help us. On the 
contrary, it should be expected that there are still more sur-
prises waiting around the corner.
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